Participants should agree to practice effective contraceptive precautions and to use at least one method of contraception for the duration of the study and for  months post-transplant
Agree to practice effective contraception
Agree to practice highly effective barrier contraception during the entire study treatment period and through  days after the last dose of the study drugs, OR
Females and males of childbearing potential must agree to practice  effective methods of contraception at the same time or agree to abstinence.
Practice true abstinence or
Female subjects of childbearing potential who agree to practice  effective methods of contraception.
Male subjects, even if surgically sterilized (i.e. Status post-vasectomy) must agree to agree to practice contraception.
Agree to practice effective barrier contraception during the entire study Treatment period and through  days after the last dose of study drug, OR
Male subjects must agree to practice contraception
Patients must not be pregnant/breast feeding and must agree to practice adequate contraception.
Females and males of childbearing potential must agree to practice  effective methods of contraception at the same time, or agree to abstinence
Agree to practice effective contraception
Women of childbearing potential and men should be advised and agree to practice effective methods of contraception during the course of study
Agree to practice effective barrier contraception during the entire study treatment period and through  days after the last dose of study drug, or
Male subjects must agree to practice contraception
Male subjects must agree to practice contraception
Male subjects must agree to practice contraception
Male subjects must agree to practice contraception.
Inability to practice contraception with condoms as prescribed by the protocol
Female patients who are of childbearing potential and all males must agree to practice true abstinence or use effective methods of contraception
Subjects with reproductive capability must agree to practice adequate contraception methods.
Subjects with reproductive capability must agree to practice adequate contraception methods.
Male patients who agree to practice effective barrier contraception.
Male patients at screening must agree to practice adequate contraception from study entry through at least  months after discontinuation of study drug.
Sexually active male patients unwilling to practice contraception while participating on the study and up to  days after completion of treatment
Male subjects must agree to practice contraception as directed
Patients who do not agree to practice effective forms of contraception
Patients of childbearing age who are unwilling to practice contraception
Agree to practice effective barrier contraception during the entire study treatment period and through  days after the last dose of study drug, AND
Patients must be willing to practice effective contraception for the duration of the study
Agree to practice highly effective barrier contraception during the entire study treatment period and through  days after the last dose of study drug (or longer, as mandated by local labeling [example, USPI, SmPC, etc]), OR
Agree to practice effective barrier contraception during the entire study treatment period and through  months after the last dose of study drug, or
All men and women must agree to practice effective contraception during the study period if not otherwise documented to be infertile
Females and males must practice true abstinence or agree to contraceptive methods throughout the study, and for up to  weeks following the last dose of CC .
Male subjects must agree to practice contraception during the study
Agree to practice effective barrier contraception during the entire study treatment period and through  months after the last dose of study drug, or
Agree to practice effective barrier contraception during the entire study treatment period and through  days after the last dose of study drug, AND
Male subjects must agree to practice contraception
Subjects with reproductive capability must agree to practice adequate contraception methods.
Male subjects must agree to practice contraception
Male subjects must agree to practice contraception
Female subjects who are postmenopausal for at least  year prior to screening. For women of child-bearing potential agree to practice  effective methods of contraception, or agree to practice true abstinence
Male subjects must agree to practice effective barrier contraception during the entire study treatment period and through  days after last dose of study drug or practice true abstinence
Female patients who are post menopausal, surgically sterile, or agree to practice  effective methods of contraception or agree to practice true abstinence, and must also agree to ongoing pregnancy testing; must also adhere to the guidelines of the lenalidomide pregnancy prevention program
Male patients who agree to practice effective barrier contraception or agree to practice true abstinence AND must adhere to the guidelines of the lenalidomide pregnancy prevention program
Female participants who are post menopausal, surgically sterile, or agree to practice  effective methods of contraception or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant
Male participants who agree to practice effective barrier contraception or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant
Patients must agree to practice adequate contraception.
Female patients who are post menopausal for at least  year, surgically sterile, or agree to practice  effective methods of contraception through  months after the last dose of study drug or agree to practice true abstinence
Male patients who, even if surgically sterilized, agree to practice effective barrier contraception through  months after the last dose of alisertib or agree to practice true abstinence
Patients who cannot or do not intend to practice effective contraception
Male participants agree to practice highly effective barrier contraception during the entire study treatment period and through  days after the last dose of TAK- and, for docetaxel, for as long as is mandated by local labeling, or agree to practice true abstinence.
Agree to practice effective barrier contraception during the entire study treatment period and through  months after the last dose of study drug, or
Agree to practice effective barrier contraception during the entire study treatment period and through  months after the last dose of study drug, or
All men and women must agree to practice effective contraception during the study period if not otherwise documented to be infertile.
Agree to practice effective barrier contraception during the entire study treatment period and through  months after the last dose of study drug, or
Agree to practice effective barrier contraception during the entire study treatment period and through  months after the last dose of study drug, or
Subjects with reproductive capability must agree to practice adequate contraception methods.
Female patients who are post menopausal, surgically sterile, or agree to practice  effective methods of contraception or agree to practice true abstinence
Male patients who agree to practice effective barrier contraception or agree to practice true abstinence
Female patients who are post menopausal, surgically sterile, or agree to practice  effective methods of contraception through  days after the last dose of study drug or agree to practice true abstinence
Male patients who agree to practice effective barrier contraception through  after the last dose of study drug or agree to practice true abstinence
Female patients who are post menopausal, surgically sterile, or agree to practice  effective methods of contraception or agree to practice true abstinence
Male patients who agree to practice effective barrier contraception or agree to practice true abstinence
Male subjects must agree to practice contraception
Patients must agree to practice contraception
Male subjects must agree to practice contraception
All men and women must agree to practice effective contraception during the study period if not otherwise documented to be infertile.
Agree to practice effective barrier contraception during the entire study treatment period and through  days after the last dose of study drug, or
Agree to practice true abstinence (which must be reviewed on a monthly basis and source documented) or agree to the use of highly effective methods of contraception from  days prior to starting azacitidine, and must agree to continue using such precautions while taking azacitidine (including dose interruptions) and for up to  days after the last dose of azacitidine. Cessation of contraception after this point should be discussed with a responsible physician
Agree to practice effective barrier contraception during the entire study treatment period and through  days after the last dose of study drug, or
